Waist Circumference Independently Associated with Breast Cancer Risk
the Cancer Therapy Advisor take:
Overall adiposity was positively associated with overall breast cancer risk — specifically waist circumference with overall risk in premenopausal and postmenopausal women, according to an article published online in the journal Cancer.
Participants enrolled in the study from 2003 to 2009 included a total of 50,884 women in a Sister Study cohort (aged 35 to 74 years).
In order to be eligible to participate, the women must have had a sister previously diagnosed with breast cancer.
Results showed 2,009 breast cancer diagnoses were made during the follow-up period (mean=5.4 years). Overall breast cancer risk had positive associations with weight, body mass index (BMI), waist circumference, and waist-to-hip ratio.
Hazard ratios (HR) for these associations were greater among postmenopausal women, women with hormonally responsive tumors, and those not currently using postmenopausal hormones.
Furthermore, waist circumference correlations continued to be present after adjusting for BMI in both postmenopausal women (81-88 cm vs. ≤80 cm: HR = 1.16; 95% CI: 1.01, 1.35 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 1.10, 1.54) and premenopausal women (81-88 cm vs. ≤80 cm: HR = 1.56; 95% CI: 1.19, 2.04 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 0.91, 1.87).
Overall adiposity was positively associated with overall breast cancer risk in premenopausal and postmenopausal women.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer
- Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma